133 related articles for article (PubMed ID: 29291067)
21. Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer.
Zhang T; Luo J; Fu Y; Li H; Ding R; Gong T; Zhang Z
Colloids Surf B Biointerfaces; 2017 Feb; 150():89-97. PubMed ID: 27898360
[TBL] [Abstract][Full Text] [Related]
22. Hydrogen-Bonded Tannic Acid-Based Anticancer Nanoparticle for Enhancement of Oral Chemotherapy.
Le Z; Chen Y; Han H; Tian H; Zhao P; Yang C; He Z; Liu L; Leong KW; Mao HQ; Liu Z; Chen Y
ACS Appl Mater Interfaces; 2018 Dec; 10(49):42186-42197. PubMed ID: 30444601
[TBL] [Abstract][Full Text] [Related]
23. Cube-shaped theranostic paclitaxel prodrug nanocrystals with surface functionalization of SPC and MPEG-DSPE for imaging and chemotherapy.
Guo F; Shang J; Zhao H; Lai K; Li Y; Fan Z; Hou Z; Su G
Colloids Surf B Biointerfaces; 2017 Dec; 160():649-660. PubMed ID: 29031225
[TBL] [Abstract][Full Text] [Related]
24. Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles.
Calleja P; Espuelas S; Vauthier C; Ponchel G; Irache JM
J Pharm Sci; 2015 Sep; 104(9):2877-86. PubMed ID: 25600579
[TBL] [Abstract][Full Text] [Related]
25. Folate-polyethyleneimine functionalized mesoporous carbon nanoparticles for enhancing oral bioavailability of paclitaxel.
Wan L; Wang X; Zhu W; Zhang C; Song A; Sun C; Jiang T; Wang S
Int J Pharm; 2015 Apr; 484(1-2):207-17. PubMed ID: 25724138
[TBL] [Abstract][Full Text] [Related]
26. Enhanced transport of nanocage stabilized pure nanodrug across intestinal epithelial barrier mimicking Listeria monocytogenes.
Xia D; Tao J; He Y; Zhu Q; Chen D; Yu M; Cui F; Gan Y
Biomaterials; 2015 Jan; 37():320-32. PubMed ID: 25453961
[TBL] [Abstract][Full Text] [Related]
27. The construction and characterization of hybrid paclitaxel-in-micelle-in-liposome systems for enhanced oral drug delivery.
Li Y; Chen Z; Cui Y; Zhai G; Li L
Colloids Surf B Biointerfaces; 2017 Dec; 160():572-580. PubMed ID: 29028605
[TBL] [Abstract][Full Text] [Related]
28. N-Deoxycholic acid-N,O-hydroxyethyl Chitosan with a Sulfhydryl Modification To Enhance the Oral Absorptive Efficiency of Paclitaxel.
Yu Y; Huo M; Fu Y; Xu W; Cai H; Yao L; Chen Q; Mu Y; Zhou J; Yin T
Mol Pharm; 2017 Dec; 14(12):4539-4550. PubMed ID: 29058910
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of intestinal permeation enhancement with carboxymethyl chitosan-rhein polymeric micelles for oral delivery of paclitaxel.
Wang X; Qiu L; Wang X; Ouyang H; Li T; Han L; Zhang X; Xu W; Chu K
Int J Pharm; 2020 Jan; 573():118840. PubMed ID: 31715358
[TBL] [Abstract][Full Text] [Related]
30. Erythrocyte membrane nanoparticles improve the intestinal absorption of paclitaxel.
Jiang X; Wang K; Zhou Z; Zhang Y; Sha H; Xu Q; Wu J; Wang J; Wu J; Hu Y; Liu B
Biochem Biophys Res Commun; 2017 Jun; 488(2):322-328. PubMed ID: 28495530
[TBL] [Abstract][Full Text] [Related]
31. Spironolactone nanocrystals for oral administration: Different pharmacokinetic performances induced by stabilizers.
Mu S; Li M; Guo M; Yang W; Wang Y; Li J; Fu Q; He Z
Colloids Surf B Biointerfaces; 2016 Nov; 147():73-80. PubMed ID: 27490456
[TBL] [Abstract][Full Text] [Related]
32. Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension.
Cao Y; Wei Z; Li M; Wang H; Yin L; Chen D; Wang Y; Chen Y; Yuan Q; Pu X; Zong L; Duan S
Curr Cancer Drug Targets; 2019; 19(4):338-347. PubMed ID: 29956630
[TBL] [Abstract][Full Text] [Related]
33. Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration.
Lv PP; Wei W; Yue H; Yang TY; Wang LY; Ma GH
Biomacromolecules; 2011 Dec; 12(12):4230-9. PubMed ID: 22044456
[TBL] [Abstract][Full Text] [Related]
34. Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel.
Zhang B; Xue A; Zhang C; Yu J; Chen W; Sun D
Pharmazie; 2016 Jun; 71(6):320-6. PubMed ID: 27455550
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
36. Current development in the formulations of non-injection administration of paclitaxel.
Du X; Khan AR; Fu M; Ji J; Yu A; Zhai G
Int J Pharm; 2018 May; 542(1-2):242-252. PubMed ID: 29555439
[TBL] [Abstract][Full Text] [Related]
37. Novel dietary lipid-based self-nanoemulsifying drug delivery systems of paclitaxel with p-gp inhibitor: implications on cytotoxicity and biopharmaceutical performance.
Sandhu PS; Beg S; Mehta F; Singh B; Trivedi P
Expert Opin Drug Deliv; 2015; 12(11):1809-22. PubMed ID: 26144859
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel-loaded Nanolipidic Carriers with Improved Oral Bioavailability and Anticancer Activity against Human Liver Carcinoma.
Harshita ; Barkat MA; Rizwanullah M; Beg S; Pottoo FH; Siddiqui S; Ahmad FJ
AAPS PharmSciTech; 2019 Jan; 20(2):87. PubMed ID: 30675689
[TBL] [Abstract][Full Text] [Related]
39. Albumin-coated nanocrystals for carrier-free delivery of paclitaxel.
Park J; Sun B; Yeo Y
J Control Release; 2017 Oct; 263():90-101. PubMed ID: 28049022
[TBL] [Abstract][Full Text] [Related]
40. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
